Researchers find that ASTX727, a new oral combination therapy, can prolong survival in TP53-mutated MDS.
https://discoveries.vanderbilthealth.com/2023/01/innovative-therapy-boosts-survival-in-myelodysplatic-syndrome/
Vanderbilt Health
Locked
